Apr 30, 2021 8:00am EDT SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
Apr 20, 2021 8:00am EDT SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting
Mar 29, 2021 8:20am EDT SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Mar 02, 2021 7:30am EST SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Feb 25, 2021 4:15pm EST SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event
Feb 23, 2021 8:15am EST SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections
Feb 17, 2021 8:15am EST SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China
Dec 22, 2020 8:00am EST SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Dec 17, 2020 9:28am EST SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Dec 16, 2020 4:21pm EST SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants
